Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Initially identified more than 30 years ago, the ETS family of transcription factors has been found to take part in all steps of tumorigenesis. This Review discusses the different mechanisms of ETS activation and the oncogenic implications of this activation, as well as how to target ETS factors in cancer treatment.
Clinical trials testing activators of tumour necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) signalling in cancer have not met expectations. This Review discusses new insights that might explain clinical failure, but also provide the basis for harnessing TRAIL-Rs for cancer therapy.
A paper inScienceby Tomasetti, Li and Vogelstein develops their 'bad luck' model further and explores how different sources of DNA mutation influence different cancer types.
Changes in the calcium signal enable cells to achieve specific outcomes. In this Review, Monteithet al. describe how the remodelling of the expression and activity of calcium channels and pumps in cancer cells can influence tumour progression.
This Review discusses the roles of deregulated RNA processing, including RNA methylation, RNA editing, RNA splicing and RNA binding protein activity, in cancer stem cells and highlights the potential of these events as biomarkers and therapeutic targets.
